Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naive Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

被引：8
|
作者：
Tantravahi, Srinivas K. [1 ]
Kishtagari, Ashwin [2 ]
Maher, Keri [3 ]
Mohan, Sanjay [4 ]
Prchal, Josef T. [5 ]
Wang, Xulong [6 ]
Chamoun, Kamal [6 ]
Walker, Christopher J. [6 ]
Taverna, Pietro [6 ]
Ali, Haris [7 ,8 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake Cty, UT USA
[2] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol, Franklin, TN USA
[3] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA
[4] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[5] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
[6] Karyopharm Therapeut, Newton, MA USA
[7] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Gehr Family Ctr Leukemia Res, Duarte, CA USA
[8] Beckman Res Inst, Duarte, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180844
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 10 条
  • [1] Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi) Treatment-Naive Patients With Myelofibrosis: Updated Results and Subgroup Analyses from XPORT-MF-034
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Prchal, Josef
    Wang, Xulong
    Chamoun, Kamal
    Tantravahi, Srinivas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S389 - S389
  • [2] Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naive patients with myelofibrosis: Updated results from XPORT-MF-034
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Prchal, Josef T.
    Wang, Xulong
    Chamoun, Kamal
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis (XPORT-MF-034)
    Maher, Keri
    Rampal, Raajit K.
    Bose, Prithviraj
    Podoltsev, Nikolai A.
    Harrison, Claire N.
    Hong, Junshik
    Wang, Xulong
    Chamoun, Kamal
    Mascarenhas, John
    BLOOD, 2023, 142
  • [4] The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naive Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification
    Passamonti, Francesco
    Foran, James M.
    Tandra, Anand
    De Stefano, Valerio
    Fox, Maria Laura
    Mattour, Ahmad H.
    McMullin, Mary Frances
    Perkins, Andrew Charles
    Rodriguez-Macias, Gabriela
    Sibai, Hassan
    Qin, Qin
    Sun, Yan
    Potluri, Jalaja
    Harb, Jason
    How, Jonathan
    BLOOD, 2022, 140
  • [5] Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).
    Mesa, Ruben A.
    Kiladjian, Jean -Jacques
    Catalano, John V.
    Devos, Timothy
    Egyed, Miklos
    Hellman, Andrzei
    McLornan, Donal
    Shimoda, Kazuya
    Winton, Elliott F.
    Deng, Wei
    Dubowy, Ronald L.
    Maltzman, Julia D.
    Cervantes, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naive Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)
    Scandura, Joseph M.
    Gerds, Aaron T.
    Ritchie, Ellen K.
    Wang, Xulong
    Kye, Steve
    Rampal, Raajit K.
    BLOOD, 2023, 142
  • [7] LONG-TERM FOLLOW UP OF A PHASE 1/2 STUDY OF SAR302503, AN ORAL JAK2 SELECTIVE INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF)
    Gotlib, J.
    Pardanani, A.
    Jamieson, C.
    Cortes, J.
    Talpaz, M.
    Stone, R.
    Gao, G.
    Zhang, J.
    Neumann, F.
    Lebedinsky, C.
    Tefferi, A.
    HAEMATOLOGICA, 2012, 97 : 145 - 145
  • [8] The MD Anderson Cancer Center (MDACC) Experience with Ruxolitinib, An Oral JAK1 and JAK2 Inhibitor, in Myelofibrosis: Long-Term Follow-up Outcomes of 107 Patients From a Phase I/II Study
    Verstovsek, Srdan
    Estrov, Zeev
    Cortes, Jorge E.
    Thomas, Deborah A.
    Borthakur, Gautam
    Kadia, Tapan
    Jabbour, Elias
    Pierce, Sherry
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1646 - 1646
  • [9] Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).
    Arora, Sankalp
    Senapati, Jayastu
    Masarova, Lucia
    Pemmaraju, Naveen
    Bose, Prithviraj
    Bravo, Guillermo Montalban
    Saenz, Dyana T.
    Halim, Habiba
    Zhou, Lingsha
    Maiti, Abhishek
    Borthakur, Gautam
    Kadia, Tapan M.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Long-Term Response to Selinexor in Patients With Myelofibrosis and Refractory or Intolerant to JAK Inhibitors: Follow-Up Results of a Single-Center, Phase II, Investigator-Initiated Trial (IIT)
    Tantravahi, Srinivas
    Patel, Ami
    Yap, Jeffrey
    Walker, Christopher
    Ellero, Andrea
    Rets, Anton
    Prchal, Josef
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S441 - S441
1